Elesclomol (STA-4783)

Catalog No.S1052

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Cited by 6 Publications

Cell, 2017, 168(1-2):86-100

PubMed: 27916275

Osteoporos Int, 2018, 29(8):1917-1926

PubMed: 29860665

BMC Genomics, 2014, 15(1):263

PubMed: 24708151

Int J Biochem Cell Biol, 2017, 85:166-174

PubMed: 28259749

Int J Radiat Biol, 2017, 93(2):194-203

PubMed: 27600766

Oncotarget, 2016, 10.18632/oncotarget.10921

PubMed: 27486766

4 Customer Reviews

Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.
Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Targets

HSP70 ^[1]
(Cell-free assay)

In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. ^[1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. ^[2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NOS-1 cell	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2W2VmlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhOy54NnWtNFUh\|ryP	MVLTRW5ITVJ?
CAL-51 cell	NYDQNo1YT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MVTJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuNVI3KG6P	MnztV2FPT0WU
ABC-1 cell	M1nZXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MmjCTY5pcWKrdHnvckBw\iCqdX3hckBCSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuN\|Y2KG6P	Mn75V2FPT0WU
A2780 cell	NEnOOIdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NILzcnNKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42QTRibl2=	MmrHV2FPT0WU
ES1 cell	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M4rrRmlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD63OFkhdk1?	NIizWWlUSU6JRWK=
HUTU-80 cell	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnO5TY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44QTFibl2=	NXXKNGFXW0GQR1XS
NCI-H292 cell	MojJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NYDwPHdUUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwOEi2JI5O	M3jBPHNCVkeHUh?=
NB69 cell	MkTlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MlP3TY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6yNkBvVQ>?	MUHTRW5ITVJ?
ES8 cell	M1;xZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NVvRToU6UW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlMzKG6P	M{DBc3NCVkeHUh?=
BCPAP cell	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVzJcohq[mm2aX;uJI9nKGi3bXHuJGJEWEGSIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6zOEBvVQ>?	NHi4V2ZUSU6JRWK=
T-24 cell	NXr1OoM4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MUHJcohq[mm2aX;uJI9nKGi3bXHuJHQuOjRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkW1JI5O	NW\xNFVJW0GQR1XS
EW-16 cell	NXnueG0yT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M4rsTmlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYyKG6P	M3f2fnNCVkeHUh?=
OVCAR-5 cell	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnrxTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OyCwTR?=	NHT2Wo5USU6JRWK=
SF126 cell	NYiwdWFXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mn;ITY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPVUhdk1?	NFK1UmdUSU6JRWK=
KP-4 cell	M2P0dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NUO4R2lWUW6qaXLpeIlwdiCxZjDoeY1idiCNUD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4yPyCwTR?=	NEfXZXFUSU6JRWK=
GAMG cell	M2npfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXnJcohq[mm2aX;uJI9nKGi3bXHuJGdCVUdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWxJI5O	NF20b\|FUSU6JRWK=
HOS cell	NIL4eVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MmPTTY5pcWKrdHnvckBw\iCqdX3hckBJV1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWzJI5O	MWjTRW5ITVJ?
CHL-1 cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NEHpV3BKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45OSCwTR?=	NUfGPGE2W0GQR1XS
AGS cell	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MkDKTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lki2JI5O	M2TmTHNCVkeHUh?=
MDA-MB-157 cell	NFmydXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Mn;GTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi57MjDuUS=>	MX\TRW5ITVJ?
HSC-3 cell	NGi5OZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MkfWTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuNFIhdk1?	NEnhWJJUSU6JRWK=
CAL-72 cell	NYL2VpV[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M3\JR2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?=	MlzWV2FPT0WU
NBsusSR cell	Mm\mS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXjJcohq[mm2aX;uJI9nKGi3bXHuJG5De3W\|U2KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlE{KG6P	M3zrPHNCVkeHUh?=
ES7 cell	MnTzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NFfpcldKdmirYnn0bY9vKG:oIHj1cYFvKEWVNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuOVkhdk1?	M3;5ZXNCVkeHUh?=
H-EMC-SS cell	NX72dlhMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MnWyTY5pcWKrdHnvckBw\iCqdX3hckBJNUWPQz3TV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjhibl2=	MXLTRW5ITVJ?
NCI-H1703 cell	NI\tT\|dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGW5[YZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVcxOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTNwNkigcm0>	Mk\mV2FPT0WU
BHT-101 cell	NGLJW4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NFTUVItKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd{IH7N	Ml7wV2FPT0WU
SK-OV-3 cell	NWnMUpMzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVrTWY9GUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55NTDuUS=>	NVfPbWgxW0GQR1XS
EW-24 cell	NWftfVNJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MoHWTY5pcWKrdHnvckBw\iCqdX3hckBGXy1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuPFMhdk1?	MlTDV2FPT0WU
PSN1 cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NXywW41uUW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45PCCwTR?=	M3jVZXNCVkeHUh?=
OVCAR-8 cell	Ml3oS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M2TXUWlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTlibl2=	M2mwdXNCVkeHUh?=
NCI-H1563 cell	NELmO\|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NFn5copKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVU3OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwMUOgcm0>	Mlj5V2FPT0WU
SW756 cell	NVnx[ZdCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVvCT4lWUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTNibl2=	NGryXWpUSU6JRWK=
A375 cell	M3;RU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGj3SYNKdmirYnn0bY9vKG:oIHj1cYFvKEF\|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE1KG6P	MnfMV2FPT0WU
Ca9-22 cell	NX3M[nNqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYPJcohq[mm2aX;uJI9nKGi3bXHuJGNiQS1{MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNlUhdk1?	MWXTRW5ITVJ?
SW1990 cell	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2rhS2lvcGmkaYTpc44hd2ZiaIXtZY4hW1dzOUmwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4{OiCwTR?=	M2rRSnNCVkeHUh?=
ES4 cell	MoH3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWDJcohq[mm2aX;uJI9nKGi3bXHuJGVUPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwM{mgcm0>	NHzpTYZUSU6JRWK=
HCE-T cell	M1Tre2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mlr6TY5pcWKrdHnvckBw\iCqdX3hckBJS0VvVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuOFUhdk1?	Mk\nV2FPT0WU
MOLT-16 cell	MlHpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NHrLOVVKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV\|IH7N	NHHRNYdUSU6JRWK=
HSC-4 cell	MoHrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXfJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND64JI5O	NEP5OIdUSU6JRWK=
NCI-SNU-1 cell	NHv3fWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NITDd4xKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwOE[gcm0>	NYLCfWxpW0GQR1XS
EW-11 cell	M2H3emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3\2O2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlkhdk1?	NIi3[ZhUSU6JRWK=
HT-1080 cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk6KG6P	MWrTRW5ITVJ?
MES-SA/Dx5 cells	MkK3R5l1d3SxeHnjbZR6KGG\|c3H5	NGTkTVREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTVNvU1GvSJg2KGOnbHzzMEBKSzVyPUWgcm0>	MkfMNlM6Ozd7OEG=
SW1710 cell	NEjGOpZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NISxbpBKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTZibl2=	NYfPclhWW0GQR1XS
EW-1 cell	NYHLXnlrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NGjMOmpKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI1KG6P	NFqx[ZFUSU6JRWK=
BV-173 cell	M{C2dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NHWwd3hKdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzlibl2=	M1;1dXNCVkeHUh?=
TE-8 cell	MnfRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MmHNTY5pcWKrdHnvckBw\iCqdX3hckBVTS16IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT60NUBvVQ>?	MV\TRW5ITVJ?
G-401 cell	NXniUoVrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NUnGS4lTUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDNibl2=	M1LxZnNCVkeHUh?=
KOSC-2 cell	MlXHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M1nZ[mlvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41PSCwTR?=	M1fqSXNCVkeHUh?=
HuCCT1 cell	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MlnOTY5pcWKrdHnvckBw\iCqdX3hckBJfUOFVEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlUzKG6P	NH7VU5VUSU6JRWK=
FADU cell	M3m2WGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3jiTmlvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuOlYhdk1?	MYrTRW5ITVJ?
MHH-ES-1 cell	MmDtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NW\q[YNTUW6qaXLpeIlwdiCxZjDoeY1idiCPSFitSXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwNkmgcm0>	NX72e2pPW0GQR1XS
ES3 cell	M17xSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NV75RlFuUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlc6KG6P	M3ruSHNCVkeHUh?=
OVCAR-4 cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NE\YW2NKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njh5IH7N	NFjLVZRUSU6JRWK=
HD-MY-Z cell	NHnpbG9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NFrzVmJKdmirYnn0bY9vKG:oIHj1cYFvKEiGLV3ZMXoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjlzIH7N	Mn3wV2FPT0WU
human JAR cell	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NIr3bHRKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuPVchdk1?	NGPyTYhUSU6JRWK=
A427 cell	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVPJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkC3JI5O	MnHFV2FPT0WU
697 cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Ml3CTY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkGzJI5O	MWjTRW5ITVJ?
OVCAR-3 cell	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MYjJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIhdk1?	NYfEO\|FMW0GQR1XS
human NB14 cell	Mlj1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NWfYfmRtUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok43PCCwTR?=	NHTv[olUSU6JRWK=
GB-1 cell	M{[xfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NX;ae4I6UW6qaXLpeIlwdiCxZjDoeY1idiCJQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44OSCwTR?=	MkfZV2FPT0WU
COR-L105 cell	NF7LfWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44PiCwTR?=	MUDTRW5ITVJ?
647-V cell	NWXPd2RVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYLSWIRrUW6qaXLpeIlwdiCxZjDoeY1idiB4NEetWkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvQSCwTR?=	M132[3NCVkeHUh?=
human K5 cell	MnPMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVruSYNiUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUegcm0>	NYSwdoFTW0GQR1XS
DMS-273 cell	M{fCPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NWXHWIdwUW6qaXLpeIlwdiCxZjDoeY1idiCGTWOtNlc{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yNjDuUS=>	NHnTN2pUSU6JRWK=
UM-UC-3 cell	MkDES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mle4TY5pcWKrdHnvckBw\iCqdX3hckBWVS2XQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?=	Mn;LV2FPT0WU
HEL cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWPpd5dRUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA5KG6P	NILPd5FUSU6JRWK=
human KU-19-19 cell	NF7IXJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NWOwVW5bUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdwMEmgcm0>	Mnz2V2FPT0WU
MC-IXC cell	NX:2UHdKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MkjQTY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlE4KG6P	MXXTRW5ITVJ?
human H4 cell	NXjwSGt3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MXjJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5{NTDuUS=>	NUHjSpBIW0GQR1XS
NUGC-3 cell	M2LpS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NV;lVFViUW6qaXLpeIlwdiCxZjDoeY1idiCQVVfDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjN\|IH7N	Mo\IV2FPT0WU
CHP-212 cell	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M4nONWlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzRibl2=	MXHTRW5ITVJ?
human SW982 cell	M3\4fGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1jZdmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlQ1KG6P	M1jUXXNCVkeHUh?=
C-33-A cell	M{DLWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NIjQT5ZKdmirYnn0bY9vKG:oIHj1cYFvKENvM{OtRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPThibl2=	NV[1R4g6W0GQR1XS
PC-3 cell	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NUjaNoplUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45QSCwTR?=	M{LWTXNCVkeHUh?=
COLO-684 cell	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmPaTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOjFibl2=	NHraW5RUSU6JRWK=
SNU-387 cell	NITkR3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NWrPZ5NOUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtN\|g4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QS52OTDuUS=>	MWDTRW5ITVJ?
U251 cell	NIXVfVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NW\3OlNEUW6qaXLpeIlwdiCxZjDoeY1idiCXMkWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU45PiCwTR?=	MWXTRW5ITVJ?
A673 cell	M2\Cd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M2fITWlvcGmkaYTpc44hd2ZiaIXtZY4hSTZ5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGxMlYhdk1?	MVzTRW5ITVJ?
human T47D cell	M{j4PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NEizTXNKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOk44QSCwTR?=	MWrTRW5ITVJ?
A549 cell	NU\nd\|lkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWLtOldWUW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVkvPiCwTR?=	NH3rWXRUSU6JRWK=
PC-14 cell	M1j3RWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NUDqSnZYUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2xOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI1Njd\|IH7N	NXXVWYx3W0GQR1XS
A704 cell	MnzaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVHJcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Nz60OUBvVQ>?	M2DYTHNCVkeHUh?=
MCF7 cell	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVLJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|MT6zOkBvVQ>?	NYPhbIR1W0GQR1XS
PC3 cells	NIDXNY5HfW6ldHnvckBie3OjeR?=	NFvWN3pKdmirYnn0bY9vKG:oIGDET\|EudWWmaXH0[YQhSUuWIIDoc5NxcG:{eXzheIlwdiCjdDDUbJI{ODhicnXzbYR2\SCrbjDoeY1idiCSQ{OgZ4VtdHNiYomgSWxKW0FuIFnDOVA:OC5zMUOg{txO	NFnsV2wzOTN2MU[3OS=>
F-36P cells	M1\RdHBzd2yrZnXyZZRqd25iYYPzZZk>	MmLBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCILUO2VEBk\WyuczygTWM2OD1yLkK4JO69VQ>?	MnfiNlE{PDF4N{W=
OCI-AML2 cells	MlK5VJJwdGmoZYLheIlwdiCjc4PhfS=>	MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:FST3BUWwzKGOnbHzzMEBKSzVyPUCuN\|Uh\|ryP	NGry[oIzOTN2MU[3OS=>
K562 cells	NVqyT5pKWHKxbHnm[ZJifGmxbjDhd5NigQ>?	MnvmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNNU[yJINmdGy\|LDDJR\|UxRTF6IN88US=>	M{XNTFIyOzRzNke1

... Click to View More Cell Line Experimental Data

In vivo

Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. ^[4]

Protocol

Cell Research:^[1]	+ Expand Cell lines: Hs294T, HSB2, and Ramos Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM Incubation Time: 18, or 24 hours Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit. (Only for Reference)
Animal Research:^[4]	+ Expand Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors Formulation: Dissolved in DMSO, and diluted in saline Dosages: ~100 mg/kg Administration: Intravenous injection (Only for Reference)

Cell Research:^[1]

+ Expand

Cell lines: Hs294T, HSB2, and Ramos
Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
Incubation Time: 18, or 24 hours
Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
(Only for Reference)

Animal Research:^[4]

+ Expand

Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
Formulation: Dissolved in DMSO, and diluted in saline
Dosages: ~100 mg/kg
Administration: Intravenous injection
(Only for Reference)

References

[4] Gehrmann M. Curr Opin Investig Drugs, 2006, 7(6), 574-580.

+ Expand

Solubility (25°C)

In vitro	DMSO	80 mg/mL (199.75 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Elesclomol (STA-4783) SDF

Molecular Weight	400.5
Formula	C₁₉H₂₀N₄O₂S₂
CAS No.	488832-69-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01280786	Unknown status	Acute Myeloid Leukemia	Synta Pharmaceuticals Corp.	January 2011	Phase 1
NCT00888615	Active not recruiting	Fallopian Tube Clear Cell Adenocarcinoma\|Fallopian Tube Endometrioid Adenocarcinoma\|Fallopian Tube Mucinous Adenocarcinoma\|Fallopian Tube Serous Adenocarcinoma\|Fallopian Tube Transitional Cell Carcinoma\|Ovarian Brenner Tumor\|Ovarian Clear Cell Adenocarcinoma\|Ovarian Endometrioid Adenocarcinoma\|Ovarian Mucinous Adenocarcinoma\|Ovarian Seromucinous Carcinoma\|Ovarian Serous Adenocarcinoma\|Ovarian Transitional Cell Tumor\|Primary Peritoneal Serous Adenocarcinoma\|Recurrent Fallopian Tube Carcinoma\|Recurrent Ovarian Carcinoma\|Recurrent Primary Peritoneal Carcinoma\|Undifferentiated Fallopian Tube Carcinoma\|Undifferentiated Ovarian Carcinoma	Gynecologic Oncology Group\|National Cancer Institute (NCI)	December 2010	Phase 2
NCT00827203	Suspended	Metastatic Solid Tumors	Synta Pharmaceuticals Corp.	January 2009	Phase 1
NCT00808418	Completed	Prostate Cancer	Synta Pharmaceuticals Corp.	November 2008	Phase 1
NCT00522834	Terminated	Melanoma	Synta Pharmaceuticals Corp.	August 2007	Phase 3
NCT00087997	Completed	Soft Tissue Sarcoma	Synta Pharmaceuticals Corp.	July 2004	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products0

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Features:Displays very low toxicity toward normal cells.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)

Cited by 6 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Elesclomol (STA-4783) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products0

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)

Cited by 6 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Elesclomol (STA-4783) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)